Skip to main page content

• HOME
• CURRENT ISSUE
• PAST ISSUES
• MOBILE
• ABOUT
• ACP
• SUBSCRIPTIONS
• E-MAIL ALERTS
• SUBMIT

RSS Feeds

1. Aspirin for the essential arterial hypertension

   • Hernando Rafael, Neurosurgeon

   Universidad Nacional Autónoma de México

   TO THE EDITOR:

   I read with interest the article by Wolff,et al. (1), about the use of aspirin into patients with coronary heart and cerebrovascular diseases. These authors concluded that the regular use of aspirin reduced the risk for myocardial infarction in men and strokes in women. However another author informs that low-dose aspirin did not reduce the risk of cardiovascular events (2), but in the prevention of ischemic stroke and other vascular events (3,4).

   I report the use of aspirin and clonazepam into two patients with essential arterial hypertension(EAH)(unpublished observations ). CASE 1: A 65-year-old man with history of EAH and treated with captopril, however, since July 2000,he received aspirin (500 mg/d) and clonazepam (2 mg/d) as supplementary medication. Four years later, his blood pressure was normalized and without anti-hypertensive therapy. CASE 2: A 62-year-old woman who suffered from stress,sleep disorders and EAH since ten months before her admission. From the first (March 2008), she received only aspirin and clonazepam. At present, one year later, her blood pressure is normal (110/60 to 120/80 mmHg). These clinical observations suggest that the regular use of aspirin may reduce or normalize EAH; due, possibly,to its anti-inflammatory and anti-thrombotic effect in the posterior hypothalamic nuclei (3,5).

   References

   1. Wolff T,Miller T,Ko S.Aspirin for the primary prevention of cardiovascular events:An update of the evidence for the U.S.Preventive services task force.Ann Intern Med 2009;150(6):405-410.

   2. Ogawa H,Nakayama M,Morimoto T,Uemura S,Kanauchi M,Doi N,et al.Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes.A randomized controlled trial.JAMA 2008;300:2134-2141.

   3. Wahner AD,Bronstein JM,Bordelon YM,Ritz B.Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 2007;69:1836-1842.

   4. Li Z-G,Yu Z-C,Wang D-Z,Ju W-P,Zhan X,Wu Q-Z,et al. Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases. Neurol Res 2008;30(4):366-369.

   5. Rafael H.Neurogenic hypertension. J Neurosurg 2003;99:1117-1118.

   Conflict of Interest:

   None declared

   Submit response
   Published March 23, 2009